Cytokeratin Pan(廣譜細胞角蛋白)

廣州健侖生物科技有限公司

AE1/AE3能識別細胞角蛋白的酸性和堿性亞家族成員，酸性成員包括分子量為56.5、55、51、50、50′ 48、46、45和40KDa的角蛋白，堿性成員包括分子量為65－67、64、59、58、56和52KDa角蛋白。AE1/AE3是一個廣譜的角蛋白抗體，對于鑒別上皮源的轉(zhuǎn)移性腫瘤有一定意義。

近年來，因廣譜抗生素的廣泛使用，使革蘭陰性菌如銅綠假單胞菌，肺炎克雷伯菌和鮑曼不動桿菌的感染日益增加，這些致病菌的耐藥嚴重，則是重癥肺炎治療困難，死亡率高的主要原因之一。在重癥肺炎治療上，宜采用抗生素降階梯療法策略，抗菌譜應盡可能覆蓋所有致病菌，可經(jīng)驗性優(yōu)先選用亞胺培南、哌拉西林—三唑巴坦和頭孢吡肟，加酶抑制劑的第三代頭孢菌素以及新喹諾酮類，獲得細菌學結(jié)果后，再根據(jù)藥敏結(jié)果和臨床情況，改用針對性強的抗生素及降階梯治療。同時必須注意對ESBLs的檢測，加強監(jiān)控和管理，防止ESBLs菌株的擴散和爆發(fā)流行。

我司還提供其它進口或國產(chǎn)試劑盒：登革熱、瘧疾、流感、A鏈球菌、合胞病毒、腮病毒、乙腦、寨卡、黃熱病、基孔肯雅熱、克錐蟲病、違禁品濫用、肺炎球菌、軍團菌、化妝品檢測、食品安全檢測等試劑盒以及日本生研細菌分型診斷血清、德國SiFin診斷血清、丹麥SSI診斷血清等產(chǎn)品。

歡迎咨詢

歡迎咨詢

Cytokeratin Pan(廣譜細胞角蛋白)

【產(chǎn)品介紹】

細胞定位：細胞漿

克隆號：AE1&AE3

同型：IgG1/K

適用組織：石蠟/冰凍

陽性對照：皮膚

抗原修復：熱修復（EDTA）

抗體孵育時間：30-60min

Cytokeratin Pan(廣譜細胞角蛋白)

想了解更多的產(chǎn)品及服務請掃描下方二維碼：

【公司名稱】 廣州健侖生物科技有限公司
【市場部】     歐

【】 
【騰訊  】 
【公司地址】 廣州清華科技園創(chuàng)新基地番禺石樓鎮(zhèn)創(chuàng)啟路63號二期2幢101-103室

AE1 / AE3 recognizes both acidic and basic subfamily members of cytokeratins, acidic members include keratins with molecular weights of 56.5, 55, 51, 50, 50, 48, 46, 45 and 40 kDa, basic members include those with a molecular weight of 65 -67, 64, 59, 58, 56 and 52 KDa keratin. AE1 / AE3 is a broad spectrum of keratin antibodies that is of interest for the identification of epithelial-derived metastatic tumors.

In recent years, due to the widespread use of broad-spectrum antibiotics, Gram-negative bacteria such as Pseudomonas aeruginosa, Klebsiella pneumoniae and Acinetobacter baumannii infections increasing, the resistance of these pathogenic bacteria is serious, is Severe pneumonia treatment difficult, one of the main causes of high mortality. In the treatment of severe pneumonia, antibiotics should be used anti-step-down therapy strategy, antibacterial spectrum should cover all pathogens as possible, empiric preferential use of imipenem, piperacillin-tazobactam and cefepime, plus enzyme Inhibitors of the third generation cephalosporins and new quinolones obtained bacteriological results, and then based on susceptibility results and clinical conditions, the switch to targeted antibiotics and the step-down treatment. At the same time, we must pay attention to the detection of ESBLs, and strengthen the monitoring and management to prevent the spreading and outbreak of ESBLs strains.